Selection of P2Y12 antagonist in patients with myocardial infarction who received thrombolytic therapy. Results of annual follow-up of TREAT study patients
Dual antiplatelet therapy serves to improve the clinical results of thrombolytic therapy after STEMI, until recently consisted of acetylsalicylic acid and clopidogrel. In this category of patients, ticagrelor, widely used by acute coronary syndrome as more effective than clopidogrel, had no serious...
Main Authors: | O. V. Averkov, V. I. Vechorko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2019-09-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3482 |
Similar Items
-
Ticagrelor and thrombolysis in myocardial infarction: what does the TREAT study change?
by: O. V. Averkov, et al.
Published: (2018-09-01) -
CLINICAL RESULTS OF THROMBOLYTIC THERAPY WITH ALTEPLASE AND TENECTEPLASE IN PATIENTS WITH MYOCARDIAL INFARCTION
by: L. A. Bondarenko, et al.
Published: (2015-12-01) -
THE RELEVANCE OF THROMBOLYTIC THERAPY IN ST ELEVATION MYOCARDIAL INFARCTION
by: N. V. Teplova, et al.
Published: (2014-05-01) -
Reasons for not receiving thrombolytic therapy in patients with acute myocardial infarction admitted to Bu-Ali Sina Hospital in Qazvin (2013-14)
by: MM. Daei, et al.
Published: (2017-04-01) -
THE PLACE FOR SYSTEMIC THROMBOLYSIS IN MODERN REPERFUSION METHODS FOR MYOCARDIAL INFARCTION
by: O. V. Averkov, et al.
Published: (2014-09-01)